Zevra Therapeutics (ZVRA) Enterprise Value (2014 - 2026)

Zevra Therapeutics has reported Enterprise Value for 13 years, with the latest figure at -$200.6 million in Q1 2026.

• For the quarter ending Q1 2026, Enterprise Value fell 220.31% year-over-year to -$200.6 million; the trailing twelve-month figure through Mar 2026 stood at -$200.6 million (down 220.31% YoY), and the FY2025 full-year result was -$191.0 million, down 174.85% from the prior year.
• Enterprise Value for Q1 2026 stood at -$200.6 million, down from -$191.0 million in the prior quarter.
• The five-year high for Enterprise Value was -$40.2 million in Q1 2023, with the low at -$202.6 million in Q2 2025.
• Historically, Enterprise Value has averaged -$101.6 million across 5 years, with a median of -$70.1 million in 2022.
• Annual changes were most pronounced in 2022 — Enterprise Value jumped 46.72% — and 2025, when it slumped 311.33%.
• Zevra Therapeutics' Enterprise Value stood at -$82.4 million in 2022, then rose by 17.76% to -$67.7 million in 2023, then declined by 2.6% to -$69.5 million in 2024, then slumped by 174.85% to -$191.0 million in 2025, then fell by 5.03% to -$200.6 million in 2026.
• The last three Enterprise Value figures came in at -$200.6 million (Q1 2026), -$191.0 million (Q4 2025), and -$199.5 million (Q3 2025), per Business Quant data.